<SEC-DOCUMENT>0000950103-24-005647.txt : 20240424
<SEC-HEADER>0000950103-24-005647.hdr.sgml : 20240424
<ACCEPTANCE-DATETIME>20240424073015
ACCESSION NUMBER:		0000950103-24-005647
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240424
DATE AS OF CHANGE:		20240424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
		CENTRAL INDEX KEY:			0001100682
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				061397316
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15943
		FILM NUMBER:		24866722

	BUSINESS ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887
		BUSINESS PHONE:		781-222-6000

	MAIL ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHARLES RIVER LABORATORIES INTERNATIONAL INC
		DATE OF NAME CHANGE:	20000605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHARLES RIVER LABORATORIES HOLDINGS INC
		DATE OF NAME CHANGE:	19991208
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>dp210186_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proxy Statement Pursuant to Section&nbsp;14(a)
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">the Securities Exchange Act of 1934 (Amendment
No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed by the Registrant </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed by a Party other than the Registrant </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check the appropriate box:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material under &sect;240.14a-12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHARLES RIVER LABORATORIES INTERNATIONAL,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Registrant as Specified In Its Charter)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Filing Fee (Check the appropriate box):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPLEMENT&nbsp;TO DEFINITIVE PROXY STATEMENT
RELATING TO<BR>
THE ANNUAL MEETING OF SHAREHOLDERS<BR>
TO BE HELD ON FRIDAY, MAY 8, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 29, 2024, Charles River Laboratories International, Inc. (&ldquo;Charles
River&rdquo; or the &ldquo;Company&rdquo;) filed a definitive proxy statement (the &ldquo;Proxy Statement&rdquo;) with the Securities
and Exchange Commission, in connection with the Company&rsquo;s Annual Meeting of Shareholders to be held on May 8, 2024. The Company
is filing this supplement to the Proxy Statement (the &ldquo;Supplement&rdquo;) relating to our opposition to Proposal Four &ndash; Shareholder
Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proposal Four in our 2024 Proxy Statement is substantially similar
to the shareholder proposal by the same proponent included in our 2023 Proxy Statement that requested a report on non-human primates (NHPs)
imported by the Company. In addition to information requested in the 2023 shareholder proposal, Proposal Four also requests zoonotic data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the rationale described in the shareholder proposal in the
Proxy Statement, and the additional information set forth in this supplement, the Board of Directors continues to recommend that shareholders
vote &ldquo;AGAINST&rdquo; Proposal Four.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE PROXY STATEMENT CONTAINS IMPORTANT ADDITIONAL
INFORMATION AND THIS&nbsp;SUPPLEMENT&nbsp;SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="width: 177px; height: 38px"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To our Shareholders,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a leading global non-clinical drug development partner,
Charles River&rsquo;s mission is to create healthier lives.&nbsp;&nbsp;We perform a vital role in the biopharmaceutical industry,
providing essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading
academic institutions around the globe to discover, develop, test and safely manufacture new therapies. The success of our strategy
is demonstrated by the fact that we have worked on more than 80% of the drugs approved by the U.S. Food and Drug Administration
(FDA) over the last five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proposal Four in our 2024 Proxy Statement requests a report on non-human
primates (NHPs) imported by the Company. As noted in the Proxy Statement, this proposal is not in the interests of the Company for the
following reasons:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="3" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As we committed to shareholders in connection with the 2023
Annual Meeting, Charles River published in March 2024 the first annual report to shareholders on measures the Company takes to reinforce
confidence that the NHPs we import are sourced in accordance with applicable laws (the &ldquo;NHP Report&rdquo;). The NHP Report may be
accessed at the following link: <I>www.criver.com/annual2024</I>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At our 2023 Annual Meeting, the same proponent put forward
a substantially similar proposal, which was unsuccessful.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of NHPs is fundamental to research and understanding
on the prevention and treatment of emerging infectious diseases, as well as the development of new innovative treatments for cancer, diabetes,
and a number of other diseases currently without effective treatment options.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles River is committed to ensuring that our operations
are compliant with applicable U.S. and international laws and regulations related to animal transportation and welfare, including all
required reporting elements. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stewardship of the research animals in our care, including
their humane care and well-being, is a core value of our Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NHP Report Meets and Exceeds What is Requested in 2024 Shareholder
Proposal Four</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NHP Report focuses on concrete initiatives being implemented to
reinforce confidence that NHPs the Company imports are sourced in accordance with applicable laws. <U>The NHP Report includes the following
information that specifically addresses all of the substantive, non-proprietary shareholder requests from Proposal Four, as well as additional
content</U> prompted by the feedback provided during our broader shareholder outreach on this topic:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="3" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Supply data on NHPs, including granular data on the global number of NHPs
placed in studies by our Safety Assessment business over the last four years;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Enhanced safeguards on proper sourcing, including development of initial
genetic testing sampling protocols to support parentage testing for purpose-bred NHPs, as well as enhanced monitoring and auditing processes;
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Details about our strengthened NHP Supplier Risk Management Process;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A commitment to annually disclose when a country of origin exceeds 30% of
globally sourced NHPs; and&nbsp;&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD>The Company specifically noted that for 2023, we procured greater than 30% of NHPs globally sourced for use in our Discovery and Safety
Assessment (DSA) segment &ndash; but less than 50% - from Cambodia. Other countries from which we import NHPs but that did not meet the
30% threshold in 2023 include, but are not limited to, Mauritius and Vietnam.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company&rsquo;s procedures to screen for zoonotic disease, and specifically:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD>All NHPs imported into our quarantine facilities first undergo a quarantine in the country of origin that includes several pathogen
screens and a thorough physical exam conducted by veterinarians. Upon arrival in the US, the NHPs then go through a second minimum 31-day
quarantine period where they go through additional tests prior to release by the Centers for Disease Control and Prevention (CDC). Charles
River also imports NHPs into Canada and Europe. In each region, we follow the same practices regarding pre-export quarantine in the source
country, import into facilities meeting the country&rsquo;s standards, and health testing that meets both governmental and Charles River
requirements.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enhanced Board and Management Oversight </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledging the importance of this issue to shareholders, in
June 2023 the Board established a separate Board committee, the Responsible Animal Use Committee (RAUC), to directly oversee these
and related matters. The RAUC was established to oversee our NHP importation practices and review, evaluate and advise the Board and
management regarding the continued enhancement of responsible animal utilization, including NHPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Also in 2023, the Company established a management-level Office for
Responsible Animal Usage to further support our commitment to responsible animal utilization and reduction practices, and operating standards
of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Committed to Respond to 2023 Shareholder Proposal Request</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Last year, Charles River responded to a substantially similar shareholder
proposal by the same proponent, with a commitment to provide shareholders with an annual report from our Board describing the efforts
we are taking to reinforce confidence that the NHPs we import are purpose-bred in accordance with applicable laws.&nbsp;&nbsp;Based on
our commitment to produce the NHP Report, the vast majority of shareholders clearly spoke and widely voted down a substantially similar
proposal from the same special interest shareholder proponent, who represented they own 22 shares of Company stock. We demonstrated fulfillment
of that commitment by engaging with shareholders as to the content of the report and producing the NHP Report prior to the 2024 Annual
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Engagement Informed Content of the NHP Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NHP report was not prepared in isolation. It was informed by significant
shareholder input.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To inform the content of the NHP Report, we conducted significant proactive
shareholder engagement reaching out to our top 25 shareholders representing more than 55% of shares outstanding, and held one-on-one discussions
in December 2023 and January 2024 with shareholders representing 15.2% of shares outstanding at the time. We met with every shareholder
who requested a discussion on this topic and other governance matters.&nbsp;Shareholder feedback was primarily focused upon NHP report topics/content, our Corporate Citizenship
Report, and updates regarding the NHP supply chain (including related legal matters).&nbsp;&nbsp;In engaging with shareholders, it became
apparent that our overall NHP sourcing process (including how we assess purpose-bred status) was of general interest to shareholders and
other constituencies, and thus we expanded the content of the NHP Report accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the shareholder outreach we proactively conducted, our
open line of communication for shareholders and other interested parties to weigh in on this topic was available &ndash; and remains available
- by writing to the Lead Director, c/o Corporate Secretary, Charles River Laboratories International, Inc., 251 Ballardvale Street, Wilmington,
Massachusetts 01887, or by email at <I>CRLLeadDirector@crl.com</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proprietary Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Charles River Board strongly believes that disclosure of further
detail related to NHPs figures by country, as requested in the shareholder proposal, is detrimental to shareholder interests as it would
benefit competitors. Our commitment to annually disclose when a country of origin exceeds 30% of globally sourced NHPs informs shareholders
regarding supply chain risk, without disclosure of overly granular confidential proprietary Company information. Proposal Four acknowledges
that proprietary information should be omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In recognition of the comprehensiveness of the NHP Report, Glass Lewis,
a leading shareholder advisory service, acknowledged that the NHP report addressed all of the matters requested, in the context of recommending
&ldquo;AGAINST&rdquo; Proposal Four.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Disclosure in Our Corporate Citizenship Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the NHP Report, Charles River also published an extensive
and comprehensive Corporate Citizenship Report in March 2024, which includes information on our Global Animal Welfare and Training, Responsible
Animal Use and New Alternative Methods (NAMs) work, including investments in NAMs through our recently launched Alternative Methods Advancement
Project (AMAP) initiative that is dedicated to investing in and developing alternatives to reduce animal testing.&nbsp;&nbsp;Our Corporate
Citizenship Report may be accessed at the following link: <FONT STYLE="background-color: white"><I>www.criver.com/annual2024. </I></FONT>A
summary of our work on NAMs and our AMAP initiative was also provided in the NHP Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Charles River is strongly and proudly committed to the responsible
use of animals in every aspect of our business. Animals are required by government regulators globally for the development and testing
of new medicines and treatments, including complex, cutting-edge biologics. Our extensive and historical commitment to &ldquo;the 4Rs&rdquo;
&ndash; Refinement, Reduction, Replacement and Responsibility &ndash; underscores our ethical framework to animal research:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="3" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Replacement</B> and investing in technology alternatives to animal testing</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reduction</B> of animals required through collaboration with clients on
study design and planning</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Refinement </B>and development of procedures to reduce impact on animals</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="3" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Responsibility</B>, the foundation of all of our efforts to advance science</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board and management of Charles River strongly believe that our
comprehensive actions and disclosure have not only met, but also exceeded, the requests for disclosure and transparency in the areas covered
in the shareholder proposal.&nbsp;&nbsp;We therefore reiterate our recommendation that shareholders should vote <B><U>AGAINST</U></B>
Proposal Four in our 2024 Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you for your consideration, as well as your support as shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James C. Foster</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin Mackay</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chair, President and Chief Executive Officer </I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chair of the Responsible Animal Use Committee of the Board of Directors</I></FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Supplement does not change or update any of the other disclosures
contained in the Proxy Statement. Except as amended or supplemented by the information contained in this supplement, all information set
forth in the Proxy Statement continues to apply and should be considered in voting your shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This supplement to the Proxy Statement is being filed with the Securities
and Exchange Commission and made available to the Company's shareholders on or about April 24, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This information is intended to supplement the Proxy Statement, which
was furnished in connection with the solicitation of proxies by the Board for use at the 2024 Annual Meeting. You are encouraged to consider
this additional information as you cast your vote on the shareholder proposal to publish a report on non-human primates imported by the
Company (Proposal Four).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Board of Directors unanimously recommends a vote &ldquo;AGAINST&rdquo;
Proposal Four.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has filed with the Securities and Exchange Commission and
provided to its shareholders the Proxy Statement and additional solicitation material in connection with the 2024 Annual Meeting. SHAREHOLDERS
ARE URGED TO READ THE PROXY STATEMENT, THE ADDITIONAL SOLICITATION MATERIALS AND OTHER RELEVANT DOCUMENTS FILED BY THE COMPANY WITH THE
SECURITIES AND EXCHANGE COMMISSION IN THEIR ENTIRETY BECAUSE THEY CONTAIN, OR WILL CONTAIN, IMPORTANT INFORMATION. Copies of these documents
may also be obtained free of charge through the Securities and Exchange Commission website at <I>www.sec.gov</I> and through the Company
website <I>www.criver.com/annual2024</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you have already voted, you do not need to vote again unless you
would like to change or revoke your prior vote on any proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F +$# 2(  A$! Q$!_\0
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M8\6:0^@:!X-\,6UI]OBDO ;FW\T1B[D4;B&8]F8D\^@KJUU_Q>BA5\";548
M&K0@ ?E0!T&CZYINOZ:NH:9=)<VS<;EZJ>X(/(/L:YU_B;X>-M;2V7V[4'N%
M9U@L[5I)%4,5RR\;1D'KUJCX7TS7K?QOJNJ7&AKI.FW]L#+"MVDH-PI&' 7I
MD$YXZT?!JQMK;X>VUS%$JS74LKS/CEB)&4<^@ ''U]: +?\ PL[2O^@1K_\
MX+GHKM:* /-]635/AQ/?ZII9MKO0[N9KB6PG=D>&4\L8V (P?0]*IZ??:I\6
MK:)9TM]-\/I*KW,$<C237&TY"$[0 N1VYHHH&=6=)F'Q0CU4-$+9='-MLR=V
M[S=W3&,8]ZZ:92T$BCJ5(_2BB@1YU8>#K^7X7Z+I\-S;1ZII=P+RWD;+1&1)
M'8!N,X(;TI+3Q[XDU2\_LJUTK2H;_P"[Y\EU(T8/KM" _AFBB@9-X4T76?#G
MCO4X[J\M]0BU2-+B>Y;*2AU4C 4#;C<>!G@ 5M>!M+GTJQU:.=XV,^JW$Z["
M3A6(P#D#FBB@0NJZ7/<?$+P_J2/&(;:WN4=23N)8 #'&*R]?TS4O"VLWOBK0
M9+9H;I5_M&QN2RK(5& Z,H.&_#%%% &%8>+M>^)T$VEZ9';Z);$[+NX\YI9M
MG<1X4 $],DUU?B#P[?PV6E7?A^^\BZT93LCN79H[B+;AEDQR3@9SZ_G110!R
M-M\8-3O]3;2+;0;1+X';YDEXQBSZX"9Q7>>#_#\_A[2ITO)XY[Z\NI+RZ>)2
MJ>8YY"@\X&!110,K>(]+GO?%OA6\C>,1V<\S2!B<G='@8XK:UVW>[\/ZE;1E
M0\MK+&I;IDH0,T44"*OA.RDT_P (:193%&DAM(XV*\@D*!QFN2T+P==6?C+R
M)KF%]"TJ66ZT^V7.Y'EQPW&,+EL?6BB@#J?%GAM/$VE) MPUK>6\JW%I=(,F
M&5>A]QZBN*N/B)XDTJ_71+W2]+N-2^X+B.Y=8B1W*[,_D:** .K\*Z!J&G"^
MU+6;\7FJZ@0TIC)$,2@?*D8/8>O4TGP\T>XT'P38Z;=/$\T32EFB)*_-(S#&
-0#WHHH ZBBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
